At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Citicolinedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neuroprotection and Neuroenhancement in a Model of Optic Nerve Neurodegeneration (Non Arteritic Ischemic Optic Neuropathy): Study of Morpho-functional Changes Related to Treatment With Citicoline Oral Solution
In Brief
A clinical study evaluating Citicoline for Non-arteritic Ischemic Optic Neuropathy. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The investigators tested the hypothesis whether the treatment with Citicoline in oral solution (OS-Citicoline) would increase or stabilize visual acuity, retinal ganglion cells (RGCs) function and neural conduction along the visual pathways (neuroenhancement), and/or induce preservation of RGCs fibers' loss (neuroprotection) in an human model of neurodegeneration: non-arteritic ischemic optic neuropathy (NAION).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-arteritic Ischemic Optic Neuropathy
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
Primary CompletionJul 2017
Study CompletionApr 2018
First PostedNov 2018
TodayJul 2026
First PostedNov 29, 2018
Enrollment StartFeb 20, 2017
Primary CompletionJul 25, 2017
Study CompletionApr 25, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.6 years ago
Interventions
Citicolinedietary
Citicoline administered in oral solution